



Drugs for Neglected Diseases *initiative*

QUALITY STATEMENT

Drugs for Neglected Diseases *initiative's* mandate is to develop new drugs or new formulations of existing drugs for people suffering from neglected diseases. Acting in the public interest, DNDi bridges existing research and development (R&D) gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. These projects are conducted in line with recognized ethical and regulatory standards. DNDi Africa Regional Office (DNDi ARO) is one of the DNDi regional offices and its mandate is to build, strengthen and sustain Regional Partnerships to Fight Neglected Diseases in the Africa region.

In pursuit of this mandate and commitment, DNDi ARO has established a Quality Management System (QMS) in line with the requirements of ISO 9001:2015 standard. In order to maintain this QMS, we commit to:

- Continually improve the performance of the Quality Management System (QMS) by building DNDi ARO's institutional capacities
- Establish, implement, and review quality objectives regularly
- Communicate the importance of meeting our interested parties' needs and obligations and the requirements of the QMS to all employees
- Engage, retain and motivate highly skilled human resource and
- Use effective communication internally and externally.

This policy shall be reviewed regularly for continued suitability.

A handwritten signature in black ink, appearing to read 'M. Wasunna', with a stylized flourish at the end.

Dr Monique Wasunna, MBChB, MSc, PhD, DTM&H, DLSHTM, FRSHTM
DIRECTOR
July 6, 2018